We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Mera Pharmaceuticals Inc (CE) | USOTC:MRPI | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0001 | 0.00 | 01:00:00 |
Delaware
|
333-23460
|
04-3683628
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
(a)
|
(i)
|
JSW was dismissed as our independent registered public accounting firm effective on June 10, 2011.
|
(ii)
|
JSW’s report on the financial statements for the years ended October 31, 2009 and 2008, did not contain any adverse opinions or disclaimers of opinion, and were not qualified or modified as to uncertainty, audit scope, or accounting principles, other than for a going concern.
|
|
|
(iii)
|
The termination of JSW and engagement of Webb and Company, P.A. was approved by our board of directors.
|
(iv)
|
We and JSW did not have any disagreements with regard to any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure for the audited financials for the two years ended October 31, 2009 and 2008 and subsequent interim period through the date of dismissal, which disagreements, if not resolved to the satisfaction of JSW, would have caused it to make reference to the subject matter of the disagreements in connection with its reports.
|
|
(v)
|
During our fiscal years ended October 31, 2009 and 2008, and subsequent interim period through the date of dismissal, we did not experience any reportable events.
|
|
(b)
|
(i)
|
On June 10, 2011, we engaged Webb & Company, P.A. to be our independent registered public accounting firm.
|
Prior to engaging Webb & Company, P.A., we had not consulted Webb regarding the application of accounting principles to a specified transaction, completed or proposed, the type of audit opinion that might be rendered on our financial statements or a reportable event, nor did we consult with Webb regarding any disagreements with its prior auditor on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of the prior auditor, would have caused it to make a reference to the subject matter of the disagreements in connection with its reports.
|
||
(ii)
|
We did not have any disagreements with JSW and therefore did not discuss any past disagreements with JSW.
|
|
(c)
|
We requested JSW furnish us with a letter addressed to the SEC stating whether it agrees with the statements made by us regarding JSW.
|
MERA PHARMACEUTICALS, INC.
|
|||||
Date:
|
June 24, 2011
|
By:
|
/s/ G
regory
F. K
owal
|
||
Gregory F. Kowal
Chief Executive Officer
|
1 Year Mera Pharmaceuticals (CE) Chart |
1 Month Mera Pharmaceuticals (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions